GlaxoSmithKline and generic pharma firms fined £45m for anti-competitive conduct

Drug giant GlaxoSmithKline (GSK) and a number of generic pharmaceuticals firms have been fined £45m in the UK for anti-competitive practices.

The fine was handed down by the UK's Competition and Markets Authority (CMA) which said Glaxo made more than £50m of payments to companies making cheaper generic versions of its anti-depressant Seroxat to delay them coming to market.